Before asking for a Semaglutide prescription

Start with what the medicine is for

A semaglutide prescription conversation begins with the health problem, then the exact product. Wegovy (semaglutide) has an approval for weight management in people who meet its criteria. Ozempic (semaglutide) injection is approved for adults with type 2 diabetes, not for weight loss.

Those are examples of their approved uses, not the complete list. The shared ingredient doesn't make every product fit every purpose. A provider weighs the likely benefit, the risks and the alternatives; a request can end without a prescription.

For compounded Semaglutide, a request to Promise Peptides goes to one of its licensed U.S. providers. They decide whether to prescribe, not everyone qualifies, and care is for U.S. patients only. Compounded medicines are not FDA-approved. Questions about how the service works go directly to that service.

What “compounded” changes

Compounding means preparing a medicine for a patient's particular needs. FDA doesn't review compounded medicines for safety, effectiveness or quality before marketing. An approved medicine's research can't establish those things for a compounded preparation.

The shortage rules matter too. FDA declared the semaglutide injection shortage resolved in February 2025. In its April 1, 2026 update, it said semaglutide was on neither the national shortage list nor the bulk-ingredient list for 503B outsourcing facilities. These register with FDA to compound sterile medicines; they need not be pharmacies and may prepare medicines without prescriptions for named patients.

For 503A pharmacies, which prepare medicines for named patients, FDA restricts regular or large-scale compounding of “essentially a copy” of an available medicine. In plain words, that can mean the same active ingredient, the same, similar or easily substitutable strength and the same route into the body. The relevant exception needs a prescriber to determine and document that a change makes a significant difference for an identified patient.

Adding a vitamin doesn't automatically meet that test. The 503B rules are separate; a provider's review isn't blanket permission to compound. These dated FDA explanations don't establish that a particular preparation is lawful.

FDA also warns that semaglutide sodium and acetate are different active ingredients from those in approved drugs. It says it lacks information showing they have the same properties and knows of no lawful basis for using those salts in compounding.

A few notes can help

The Wegovy label's warnings make health history important. Relevant topics include a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or MEN 2 (an inherited condition), past pancreas or gallbladder trouble, serious stomach problems and diabetic eye disease. Pregnancy plans, other medicines and upcoming anesthesia matter too.

• What is the exact product, and why does it fit my health problem?
• What other options are there?
• Which side effects need attention, and who answers questions later?
• What would count as useful progress for my health problem?

Questions about unclear liquid measurements belong with the prescriber or dispensing professional. FDA has reported serious errors with compounded injectable semaglutide. The doses page explains the terms without turning them into a personal schedule.